top of page
Personalize Treatment: Quickly identifying and applying the most effective therapeutic approach for each patient.
Adapt in Real Time: Standardizing biomarker discovery and developing dynamic treatment strategies that can adapt in real-time to tumor evolution.
Revolutionize Clinical Trials: Significantly accelerating the development and implementation of targeted therapies.
In 2024, ARPA-H launched the ADAPT program, investing $142 million to improve how we treat advanced cancers. ASCEND-CRC program is one of three ADAPT trials, focusing on metastatic colorectal cancer and aiming to:
OUR MISSION:
Advancing Cancer Research
250
300
23.1M
PATIENTS
FIRST PHASE
PATIENTS
SECOND PHASE
IN GRANT FUNDING
FUNDED AND SUPPORTED BY
bottom of page